UPDATE: Citi Upgrades Eli Lilly (LLY) to Buy

(Updated - April 29, 2015 9:58 AM EDT)

Citi upgraded Eli Lilly (NYSE: LLY) from Neutral to Buy with a price target of $100. Analysts raised evacetrapib risk peak sales estimates from $1 billion to $3.8 billion. The change follows Merck (NYSE: MRK) IMPROVE-IT data that showed its Vytorin validates cardio benefit of lowering LDL cholesterol with a non-statin agent.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $71.18 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Upgrades BlackLine (BL) to Neutral
• Citi: 'Very high likelihood' of a positive Q1 EPS surprise
• CFRA Upgrades Infosys Technologies (INFY) to Buy